1. Home
  2. SLN vs TEN Comparison

SLN vs TEN Comparison

Compare SLN & TEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • TEN
  • Stock Information
  • Founded
  • SLN 1994
  • TEN 1993
  • Country
  • SLN United Kingdom
  • TEN Greece
  • Employees
  • SLN N/A
  • TEN N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • TEN
  • Sector
  • SLN Health Care
  • TEN
  • Exchange
  • SLN Nasdaq
  • TEN NYSE
  • Market Cap
  • SLN 842.4M
  • TEN 772.2M
  • IPO Year
  • SLN N/A
  • TEN N/A
  • Fundamental
  • Price
  • SLN $12.70
  • TEN $20.24
  • Analyst Decision
  • SLN Strong Buy
  • TEN Hold
  • Analyst Count
  • SLN 4
  • TEN 1
  • Target Price
  • SLN $61.50
  • TEN $24.00
  • AVG Volume (30 Days)
  • SLN 184.3K
  • TEN 385.6K
  • Earning Date
  • SLN 11-14-2024
  • TEN 11-26-2024
  • Dividend Yield
  • SLN N/A
  • TEN 8.90%
  • EPS Growth
  • SLN N/A
  • TEN N/A
  • EPS
  • SLN N/A
  • TEN 5.66
  • Revenue
  • SLN $21,773,221.00
  • TEN $822,543,000.00
  • Revenue This Year
  • SLN N/A
  • TEN N/A
  • Revenue Next Year
  • SLN $104.98
  • TEN $10.35
  • P/E Ratio
  • SLN N/A
  • TEN $3.57
  • Revenue Growth
  • SLN N/A
  • TEN N/A
  • 52 Week Low
  • SLN $8.94
  • TEN $18.88
  • 52 Week High
  • SLN $27.72
  • TEN $31.48
  • Technical
  • Relative Strength Index (RSI)
  • SLN 15.31
  • TEN 29.41
  • Support Level
  • SLN $17.11
  • TEN $20.02
  • Resistance Level
  • SLN $18.24
  • TEN $21.34
  • Average True Range (ATR)
  • SLN 0.89
  • TEN 0.73
  • MACD
  • SLN -0.49
  • TEN -0.05
  • Stochastic Oscillator
  • SLN 1.06
  • TEN 8.06

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About TEN TSAKOS ENERGY NAVIGATION

Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.

Share on Social Networks: